Celltherapy in chronic and degenerative liver diseases

FORSCHUNG UND KLINIK AG © INSTITUT PAUL NIEHANS

Cell therapy in chronic degenerative liver diseases

Dr. J. Stein, Heidelberg, Germany

Summary:

The cell therapy introduced and developed by P. Niehans has over a period of 70 years given good therapeutic results in chronic degenerative liver disease. Since 1954 the initially empirical results have been substantiated by systematic basic research. Animal experimental studies in rats whose livers had been damaged with carbon tetrachloride showed therapeutically favourable measured effects of liver-cell implantations on various parameters. The investigators arrived at the same positive results with the use of radioactively labelled liver tissue.

In the world literature, since 1916, there are many experimental studies - independent of cell therapy - which demonstrate a regenerative and reconstitutive effect of liver implants on the damaged livers of laboratory animals.

Since 1953 extensive clinical studies have also been carried out with cell therapy, which all concur in demonstrating the therapeutic effect of cell implantations in patients with chronic liver disease.

Cell therapy is indicated in chronically persistent hepatitis and its transitional stages to cirrhosis of the liver. Compensated cirrhosis of the liver is also a suitable indication for cell therapy. Cell implantations are also indicated in alcoholic hepatosis, alcoholic toxic cirrhosis and fatty degeneration of the liver. Cell therapy gives very good results in toxic hepatosis due to drug-induced liver damage-Cell therapy is contraindicated in acute hepatitis, chronic aggressive hepatitis and in decompensated cirrhosis of the liver with portal hypertension, ascities and oesophageal varices.